NASDAQ:RUBY Rubius Therapeutics (RUBY) Stock Forecast, Price & News $0.02 0.00 (0.00%) (As of 09/25/2023 ET) Add Compare Share Share Today's Range$0.0032▼$0.016250-Day Range$0.02▼$0.0252-Week Range$0.00▼$0.50Volume31,816 shsAverage Volume1.54 million shsMarket Capitalization$1.46 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability About Rubius Therapeutics (NASDAQ:RUBY) StockRubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.Read More RUBY Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RUBY Stock News HeadlinesAugust 2, 2023 | uk.finance.yahoo.comRUBY - Rubius Therapeutics, Inc.July 25, 2023 | morningstar.comNorth American Morning Briefing: Alphabet, -2-September 26, 2023 | Legacy Research (Ad)WARNING: Mandatory U.S. Dollar Recall is Weeks AwayIf you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.March 2, 2023 | finance.yahoo.comRubius Therapeutics Outlines Dissolution Plan, After Unsuccessful Attempt On AlternativesFebruary 14, 2023 | marketwatch.comThinking about buying stock in Sorrento Therapeutics, Rubius Therapeutics, Ideanomics, SoundHound AI, or C3.ai?February 14, 2023 | msn.comWhy Is Rubius Therapeutics (RUBY) Stock Up 35% Today?January 25, 2023 | yahoo.comThe Wrap: Ruby's moving to Congress Street, launching new French conceptJanuary 12, 2023 | mirror.co.ukRuby Wax sparks concern from fans after posting video from hospital bedSeptember 26, 2023 | Legacy Research (Ad)WARNING: Mandatory U.S. Dollar Recall is Weeks AwayIf you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.January 12, 2023 | dailymail.co.ukRuby Wax sparks concern amongst fans with her latest appearance from a hospital bed promoting bookNovember 18, 2022 | finance.yahoo.comFormer Rubius CEO jumps to another Flagship spinoutNovember 4, 2022 | finance.yahoo.comRubius Therapeutics lays off most of its staff, explores saleNovember 3, 2022 | finance.yahoo.comRubius Therapeutics Cuts Almost 85% Of Its Workforce, Starts Looking For Strategic AlternativesNovember 2, 2022 | seekingalpha.comRubius stock falls over 5% after hours on strategic review, more job cutsNovember 2, 2022 | finance.yahoo.comRubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership ChangesOctober 28, 2022 | finance.yahoo.comRubius Therapeutics, Inc. (RUBY)October 10, 2022 | reuters.comRubius Therapeutics IncSeptember 19, 2022 | bizjournals.comFlagship-backed Vesalius lays off 43%September 19, 2022 | finance.yahoo.comRubius Therapeutics to Present at Guggenheim Nantucket Therapeutics ConferenceSeptember 14, 2022 | bizjournals.comRubius Therapeutics lays off 75% of staff, looks to sell Smithfield facilitySeptember 13, 2022 | finance.yahoo.comRubius Therapeutics Shifts Its Clinical Focus, Pulls Plug On Two Early-Stage Cancer AssetsSeptember 13, 2022 | finance.yahoo.comRubius Therapeutics scraps platform, lays off 160September 13, 2022 | seekingalpha.comRubius stock slumps 26% as tumor trials of RTX-240, RTX-224 axed, cuts 75% workforceSeptember 13, 2022 | nasdaq.comRubius To Discontinue Clinical Trials Of RTX-240, RTX-224 - Quick FactsSeptember 13, 2022 | finance.yahoo.comRubius Therapeutics Announces Strategic UpdateSeptember 12, 2022 | financialpost.comRubius Therapeutics to Provide Strategic UpdateSeptember 7, 2022 | msn.comPeering Into Rubius Therapeutics's Recent Short InterestSee More Headlines Receive RUBY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rubius Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RUBY Company Calendar Last Earnings11/08/2021Today9/25/2023Next Earnings (Estimated)11/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RUBY CUSIPN/A CIK1709401 Webwww.rubiustx.com Phone(508) 543-1720FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-179,670,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-212.29% Return on Assets-86.74% Debt Debt-to-Equity RatioN/A Current Ratio2.54 Quick Ratio2.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.17 per share Price / Book0.10Miscellaneous Outstanding Shares90,480,000Free Float85,687,000Market Cap$1.46 million OptionableNot Optionable Beta2.34 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Laurence A. Turka M.D. (Age 65)Chief Scientific Officer and Head of Research & Translational Medicine Comp: $626.55kMr. Craig R. Jalbert CIRA (Age 61)Pres, Treasurer, CS, Principal Exe Officer, Interim Principal Fin. & Acc. Off. and Director Ms. Marissa HanifyDirector of Corp. CommunicationsKey CompetitorsIgnyte AcquisitionNASDAQ:IGNYBrickell BiotechNASDAQ:BBIScinai ImmunotherapeuticsNASDAQ:SCNISQZ BiotechnologiesNYSE:SQZKiromic BioPharmaNASDAQ:KRBPView All CompetitorsInsiders & InstitutionsSimplex Trading LLCSold 300 shares on 8/4/2023Ownership: 0.000%Dannielle AppelhansSold 10,385 sharesTotal: $1,350.05 ($0.13/share)Dannielle AppelhansSold 3,878 sharesTotal: $969.50 ($0.25/share)Pablo J CagnoniSold 7,240 sharesTotal: $1,737.60 ($0.24/share)Laurence A TurkaSold 2,593 sharesTotal: $622.32 ($0.24/share)View All Insider TransactionsView All Institutional Transactions RUBY Stock - Frequently Asked Questions How have RUBY shares performed in 2023? Rubius Therapeutics' stock was trading at $0.1750 at the beginning of 2023. Since then, RUBY stock has decreased by 90.8% and is now trading at $0.0162. View the best growth stocks for 2023 here. When is Rubius Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023. View our RUBY earnings forecast. How were Rubius Therapeutics' earnings last quarter? Rubius Therapeutics, Inc. (NASDAQ:RUBY) announced its quarterly earnings results on Monday, November, 8th. The company reported ($0.55) earnings per share for the quarter, beating analysts' consensus estimates of ($0.56) by $0.01. During the same period in the previous year, the firm earned ($0.51) EPS. What is Pablo Cagnoni's approval rating as Rubius Therapeutics' CEO? 12 employees have rated Rubius Therapeutics Chief Executive Officer Pablo Cagnoni on Glassdoor.com. Pablo Cagnoni has an approval rating of 91% among the company's employees. This puts Pablo Cagnoni in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Rubius Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rubius Therapeutics investors own include Sorrento Therapeutics (SRNE), Marinus Pharmaceuticals (MRNS), Xeris Biopharma (XERS), Fulcrum Therapeutics (FULC), Recro Pharma (REPH), TG Therapeutics (TGTX), Tilray (TLRY), Viking Therapeutics (VKTX), ADMA Biologics (ADMA) and Adverum Biotechnologies (ADVM). When did Rubius Therapeutics IPO? (RUBY) raised $200 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 9,500,000 shares at $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners served as the underwriters for the IPO. What is Rubius Therapeutics' stock symbol? Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY." Who are Rubius Therapeutics' major shareholders? Rubius Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Simplex Trading LLC (0.00%). Insiders that own company stock include Dannielle Appelhans, David R Epstein, Laurence A Turka, Maiken Keson-Brookes, Pablo J Cagnoni and Ventures Fund Iv Gene Flagship. View institutional ownership trends. How do I buy shares of Rubius Therapeutics? Shares of RUBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Rubius Therapeutics' stock price today? One share of RUBY stock can currently be purchased for approximately $0.02. How much money does Rubius Therapeutics make? Rubius Therapeutics (NASDAQ:RUBY) has a market capitalization of $1.46 million. The company earns $-179,670,000.00 in net income (profit) each year or ($2.38) on an earnings per share basis. How can I contact Rubius Therapeutics? Rubius Therapeutics' mailing address is 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139. The official website for the company is www.rubiustx.com. The company can be reached via phone at (508) 543-1720 or via email at ir@rubiustx.com. This page (NASDAQ:RUBY) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rubius Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.